Caricamento...
Impaired Retinal Circulation during Axitinib Treatment for Metastatic Renal Cell Carcinoma
PURPOSE: Axitinib, an orally administered vascular endothelial growth factor receptors 1, 2, and 3 inhibitor, is widely used as the second-line treatment for metastatic renal cell carcinoma. We present a case of metastatic renal cell carcinoma who developed a novel ocular adverse event, impaired ret...
Salvato in:
| Pubblicato in: | Case Rep Ophthalmol |
|---|---|
| Autori principali: | , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
S. Karger AG
2019
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6489367/ https://ncbi.nlm.nih.gov/pubmed/31097940 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000496197 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|